(Q40424271)

20 September 2017

1 reference

title

Options for therapy in chronic myeloid leukaemia (English)

1 reference

20 September 2017

1 reference

A. Spencer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7577633

19 May 2024

S. G. O'Brien

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7577633

19 May 2024

J. M. Goldman

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7577633

19 May 2024

language of work or name

English

0 references

publication date

1 September 1995

1 reference

full work available at URL

20 September 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2141.1995.tb05236.x

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1995.TB05236.X

https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2141.1995.tb05236.x

19 May 2024

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1995.TB05236.X

British Journal of Haematology

19 May 2024

published in

1 reference

20 September 2017

volume

91

1 reference

20 September 2017

issue

1

1 reference

20 September 2017

page(s)

2-7

1 reference

UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB05236.X

Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB05236.X

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB05236.X

Chronic myelocytic leukemia: Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB05236.X

Management of chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB05236.X

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB05236.X

Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. A comparison of complications in the first 2 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB05236.X

Involvement of the B-lymphoid system in chronic myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB05236.X

In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB05236.X

BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB05236.X

Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.1995.TB05236.X

Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. A report by the EBMT Leukaemia Working Party

21 January 2018

4

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1995.TB05236.X

Chronic Granulocytic Leukaemia with Ph1 Negative Cells in Bone Marrow and a Ten Year Remission after Busulphan Hypoplasia

19 May 2024

17

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1995.TB05236.X

Autografting for patients with CML in chronic phase: an update. Hammersmith BMT Team LRF Centre for Adult Leukaemia

19 May 2024

26

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1995.TB05236.X

Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service

19 May 2024

29

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1995.TB05236.X

Current approaches to hematopoietic stem-cell purging in chronic myeloid leukemia

19 May 2024

38

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1995.TB05236.X

Karyotypic conversion in Ph1-positive chronic myeloid leukaemia with combination chemotherapy

19 May 2024

43

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1995.TB05236.X

Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia

19 May 2024

46

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1995.TB05236.X

Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia

19 May 2024

48

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1995.TB05236.X

Marrow transplantation for the treatment of chronic myelogenous leukemia

19 May 2024

49

1 reference

https://api.crossref.org/works/10.1111/J.1365-2141.1995.TB05236.X

19 May 2024

Identifiers

1 reference

20 September 2017

1 reference